Patent estate

Senju Pharmaceutical Co., Ltd. — Patent Portfolio

1 drug with active patents · 18 active patents · 0 expired · 0 biologics with BPCIA exclusivity

AI-enriched 18/18 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

§
Strategic Patent Estate Brief
AI-grounded executive summary · generated 2026-05-16

Verdict Senju Pharmaceutical Co., Ltd.'s portfolio is moderately strong with a significant cliff year in 2029 and no revenue at risk in the next 5 years.

Portfolio overview Senju Pharmaceutical Co., Ltd. has a total of 5 drugs in its portfolio, with 1 of them having patents. The company has a total of 18 US patents, all of which are active. The average vulnerability score of these patents is 69, indicating a moderate level of vulnerability. Out of the total patents, 0 are considered ironclad, while 10 are considered vulnerable.

Cliff calendar In 2029, 1 drug will lose exclusivity, including Alphagan. This marks a significant cliff year for the company.

Most exposed drugs The top drug facing near-term loss of exclusivity is Alphagan, with an earliest active patent expiry date of 2029-07-27, an average vulnerability score of 69, and no annual revenue data available. This drug has 18 patents associated with it.

Biologic exclusivity Senju Pharmaceutical Co., Ltd. does not have any biologics in its portfolio.

Strategic implications The company has no revenue at risk in the next 5 years. However, the loss of exclusivity for Alphagan in 2029 may require the company to consider lifecycle moves such as subQ switches, label extensions, or combination filings to maintain revenue.

Sources: FDA Orange Book · FDA Purple Book · INPADOC family · USPTO · vulnerability scoring. Not legal advice.

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

1 2029 1 2030 1 2031

Patent estate by drug

Alphagan (BRIMONIDINE TARTRATE)

Cliff 2029 · 3y
Method of Use 14 Formulation 4
  • US11596600 Vuln 81 2029-07-27
    This patent protects compositions, preferably containing brimonidine, for inducing vasoconstriction at low concentrations.
  • US8455494 Vuln 81 2030-05-24
    This patent protects a pharmaceutical preparation and method for treating presbyopia using a combination of parasympathomimetic drugs and alpha agonists or antagonists.
  • US9259425 Vuln 81 2030-07-14
    This patent protects compositions and methods for whitening eyes using low concentrations of selective α-2 adrenergic receptor agonists, preferably including brimonidine.
See all 18 patents →

Patent classification breakdown · active patents

By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.

  • Method of Use 14 patents
  • Formulation 4 patents

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track Senju Pharmaceutical Co., Ltd.'s patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export